Login to Your Account

OctoPlus Shares Rise on Locteron Deal with Biolex

By Cormac Sheridan

Wednesday, October 8, 2008
Despite Monday's carnage on stock exchanges across the globe, OctoPlus NV posted a 13.6 percent rise in its share price on news that it could earn up to $149 million in up front, milestone and production-related payments from out-licensing its controlled-release formulation of alpha interferon, Locteron, to its co-development partner Biolex Therapeutics Inc. It also would receive royalties on product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription